Company intelligence / Profile preview

Autobahn Labs

Palo Alto, California, USAautobahn-labs.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Autobahn Labs has funded at least twelve early-stage therapeutic programs since its founding in late 2019. These span multiple disease areas and modalities. Its model emphasizes de-risking novel biology emerging from academia by providing funding, operational expertise, and access to industrial-scale drug discovery resources. Programs are advanced through key preclinical milestones before being spun out as independent NewCos or licensed.

Therapeutic areas: GastroenterologyEndocrinologyHematologyOncologyRare DiseasesNeurology
Modalities: Small moleculeBiologicAntibodyPeptides
Industry: Investors

Partnerships

Charles River LaboratoriesEvotecKCK GroupUCSFUCLAUCSDCold Spring Harbor LaboratoryBoston Children’s HospitalUniversity of PennsylvaniaSalk Institute for Biological Studies

Beyond the preview

Go deeper on Autobahn Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autobahn Labs.

Explore the full profile